Literature DB >> 28781801

Prognostic significance of osteopontin in acute myeloid leukemia: A meta-analysis.

Yong-Bing Chen1, Si-Mei Ren2, Si-Dan Li3, Zhongli Du2.   

Abstract

Osteopontin (OPN) has been investigated in the field of tumor research for several years. However, the prognostic role of OPN overexpression in acute myeloid leukemia (AML) remains controversial. A meta-analysis of four studies, including a total of 492 patients, was performed to determine the association of OPN with overall survival (OS) in AML patients. The random-effects model of Der Simonian and Laird was used to synthesize data; hazard ratio (HR) with its 95% confidence interval (CI) was used as the effect size estimate. It was observed that serum-based OPN was inversely correlated with OS and the difference was statistically significant (HR=1.83; 95% CI: 1.43-2.35; P<0.001). Experimental findings indicate that OPN overexpression is associated with a poor prognosis in AML and may be of prognostic value for AML stage and metastasis.

Entities:  

Keywords:  acute myeloid leukemia; meta-analysis; osteopontin; prognosis

Year:  2017        PMID: 28781801      PMCID: PMC5532631          DOI: 10.3892/mco.2017.1302

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

1.  Randomized controlled trials of treatments for hematologic malignancies: study characteristics and outcomes.

Authors:  Masamitsu Yanada; Hiroto Narimatsu; Takeshi Suzuki; Keitaro Matsuo; Tomoki Naoe
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

2.  Studies of WT1 gene expression in leukemia patients.

Authors:  Zhongxia Huang; Bai Xiao; Shilun Chen; Shulan Li; Yingmei Liu; Jingzhong Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2002-07

3.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

4.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

5.  Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.

Authors:  Ruediger Liersch; Joachim Gerss; Christoph Schliemann; Michael Bayer; Christian Schwöppe; Christoph Biermann; Iris Appelmann; Torsten Kessler; Bob Löwenberg; Thomas Büchner; Wolfgang Hiddemann; Carsten Müller-Tidow; Wolfgang E Berdel; Rolf Mesters
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

Review 6.  CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.

Authors:  J A Burger; A Peled
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis.

Authors:  Hao-Guang Wan; Hao Xu; Yu-Ming Gu; Hui Wang; Wei Xu; Mao-Heng Zu
Journal:  Clin Res Hepatol Gastroenterol       Date:  2014-07-14       Impact factor: 2.947

Review 9.  Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.

Authors:  M Colombo; L Mirandola; N Platonova; L Apicella; A Basile; A J Figueroa; E Cobos; M Chiriva-Internati; R Chiaramonte
Journal:  Leukemia       Date:  2013-01-11       Impact factor: 11.528

10.  Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.

Authors:  Aikaterini Sfiridaki; Spiros Miyakis; Constantina Pappa; George Tsirakis; Athanasios Alegakis; Vasileios Kotsis; Efstathios Stathopoulos; Michael Alexandrakis
Journal:  J Hematol Oncol       Date:  2011-05-08       Impact factor: 17.388

View more
  6 in total

1.  A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia.

Authors:  Ninib Baryawno; Dariusz Przybylski; Monika S Kowalczyk; Youmna Kfoury; Nicolas Severe; Karin Gustafsson; Konstantinos D Kokkaliaris; Francois Mercier; Marcin Tabaka; Matan Hofree; Danielle Dionne; Ani Papazian; Dongjun Lee; Orr Ashenberg; Ayshwarya Subramanian; Eeshit Dhaval Vaishnav; Orit Rozenblatt-Rosen; Aviv Regev; David T Scadden
Journal:  Cell       Date:  2019-05-23       Impact factor: 41.582

Review 2.  The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Authors:  Silje Johansen; Annette K Brenner; Sushma Bartaula-Brevik; Håkon Reikvam; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

3.  A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells.

Authors:  Mazin Gh Al-Asadi; Grace Brindle; Marcos Castellanos; Sean T May; Ken I Mills; Nigel H Russell; Claire H Seedhouse; Monica Pallis
Journal:  Oncotarget       Date:  2017-11-30

4.  Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.

Authors:  Mara W Rosenberg; Kevin Watanabe-Smith; Jeffrey W Tyner; Cristina E Tognon; Brian J Druker; Uma Borate
Journal:  Oncotarget       Date:  2020-07-21

5.  Therapeutic effect of TRC105 and decitabine combination in AML xenografts.

Authors:  June Baik; Martin Felices; Ashley Yingst; Charles P Theuer; Michael R Verneris; Jeffrey S Miller; Rita Perlingeiro
Journal:  Heliyon       Date:  2020-10-13

6.  Salivary Osteopontin as a Potential Biomarker for Oral Mucositis.

Authors:  Enikő Gebri; Attila Kiss; Ferenc Tóth; Tibor Hortobágyi
Journal:  Metabolites       Date:  2021-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.